Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS.
Gebrehiwet P, Meng L, Rudnicki SA, Sarocco P, Wei J, Wolff AA, Butzner M, Chiò A, Andrews JA, Genge A, Hughes DA, Jackson CE, Lechtzin N, Miller TM, Shefner JM.
Gebrehiwet P, et al. Among authors: butzner m.
J Med Econ. 2023 Jan-Dec;26(1):488-493. doi: 10.1080/13696998.2023.2192588.
J Med Econ. 2023.
PMID: 36930042
Free article.
Clinical Trial.